Compare PGNY & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PGNY | URGN |
|---|---|---|
| Founded | 2008 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.2B |
| IPO Year | 2019 | 2016 |
| Metric | PGNY | URGN |
|---|---|---|
| Price | $36.37 | $25.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 7 |
| Target Price | $36.67 | ★ $60.71 |
| AVG Volume (30 Days) | 995.8K | ★ 1.2M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $1,288,661,000.00 | $1,128,000.00 |
| Revenue This Year | $6.82 | $190.44 |
| Revenue Next Year | $11.43 | $69.25 |
| P/E Ratio | $38.33 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.10 | $16.50 |
| 52 Week High | $36.43 | $50.81 |
| Indicator | PGNY | URGN |
|---|---|---|
| Relative Strength Index (RSI) | 81.77 | 26.38 |
| Support Level | $24.89 | $22.61 |
| Resistance Level | N/A | $27.76 |
| Average True Range (ATR) | 1.15 | 1.98 |
| MACD | 0.82 | -0.62 |
| Stochastic Oscillator | 97.38 | 13.98 |
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.